外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义

doi:10.6040/j.issn.1671-7554.0.2020.1127

摘要/Abstract

摘要： 目的探讨长链非编码 RNA(lncRNA)OGFRP1 在非小细胞肺癌(NSCLC)血清外泌体中的表达及临床意义。方法分别对84例初诊为NSCLC的患者及84例正常健康者的血清进行外泌体提取鉴定、RNA提取及检测lncRNA表达。统计学分析血清外泌体lncRNA OGFRP1诊断NSCLC的灵敏度、特异度与准确性,分析 lncRNA OGFRP1 的表达与临床病理特征的关系。结果 84例初诊为NSCLC的患者均经病理学证实为NSCLC。lncRNA OGFRP1 在NSCLC血清外泌体中显著高表达(χ2=96.459,P<0.001)。以病理诊断为金标准,lncRNA OGFRP1测值对NSCLC的辅助诊断的灵敏度、特异度和准确性分别为90.5%、86.9%和93.9%,高于癌胚抗原,差异有统计学意义(P<0.001)。血清外泌体lncRNA OGFRP1的相对表达量与NSCLC癌患者的淋巴结转移(P=0.034)以及T分期(P=0.030)差异有统计学意义。结论血清外泌体lncRNA OGFRP1 的检测对于诊断NSCLC具有较高的灵敏度、特异度和准确性,可作为NSCLC早期筛选、检测和分期的新型肿瘤标志物。

关键词: 非小细胞肺癌, 长链非编码RNA OGFRP1, 外泌体, 癌胚抗原

Abstract: Objective To explore the expression and clinical significance of long non-coding RNA(lncRNA)OGFRP1 in serum exosomes of non-small cell lung cancer(NSCLC). Methods A total of 84 cases preliminarily diagnosed as NSCLC and 84 healthy controls were enrolled. The serum exosomes were extracted and identified, the RNA was extracted, and lncRNA expression was detected. The sensitivity, specificity and diagnostic accuracy of lncRNA OGFRP1 were statistically analyzed. The relationship between the lncRNA OGFRP1 expression and clinicopathological factors were analyzed. Results All cases were pathologically confirmed as NSCLC. lncRNA OGFRP1 was highly expressed in NSCLC(χ2=96.459, P<0.001). With pathological diagnosis as the gold standard, the sensitivity, specificity and accuracy of lncRNA OGFRP1 in the auxiliary diagnosis of NSCLC were 89.4%, 87.9% and 89.4%, respectively, higher than those of carcino-embryonic antigen(P<0.01). The relative expression of lncRNA OGFRP1 in serum exosomes was significantly associated with lymph node metastasis(P=0.034)and T stage(P=0.030)in NSCLC patients. Conclusion The detection of exosomal lncRNA OGFRP1 has high sensitivity, specificity and accuracy in the diagnosis of NSCLC, which can be used as a novel tumor marker for early screening, diagnosis and staging of NSCLC.

Key words: Non-small cell lung cancer, Long non-coding RNA OGFRP1, Exosome, Carcino-embryonic Antigen

中图分类号:

R734.2

刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.

LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer[J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update [J]. Mol Cancer, 2008, 7: 81. doi: 10.1186/1476-4598-7-81.
[3] Boolell V, Alamgeer M, Watkins DN, et al. The evolution of therapies in non-small cell lung cancer [J]. Cancers(Basel), 2015,7(3):1815-1846.
[4] Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era [J]. Mod Pathol, 2019, 32(Suppl 1): 16-26.
[5] Kadara H, Scheet P, Wistuba II, et al. Early events in the molecular pathogenesis of lung cancer [J]. Cancer Prev Res(Phila), 2016, 9(7): 518-527.
[6] Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression [J]. Genome Res, 2012, 22(9): 1775-1789.
[7] Harrow J, Frankish A, Gonzalez JM, et al. GENCODE: the reference human genome annotation for the ENCODE Project [J]. Genome Res, 2012, 22(9): 1760-1774.
[8] Chen R, Xu X, Qian Z, et al. The biological functions and clinical applications of exosomes in lung cancer [J]. Cell Mol Life Sci, 2019, 76(23): 4613-4633.
[9] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[10] Fong KM, Minna JD. Molecular biology of lung cancer: clinical implications [J]. Clin Chest Med, 2002, 23(1): 83-101.
[11] Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions [J]. Oncologist, 2008(Suppl 1): 5-13. doi: 10.1634/theoncologist.13-S1-5.
[12] Kalluri R. The biology and function of exosomes in cancer [J]. J Clin Invest, 2016, 126(4): 1208-1215.
[13] Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication [J]. Int J Biochem Cell Biol, 2012, 44(1): 11-15.
[14] Gross JC, Chaudhary V, Bartscherer K, et al. Active wnt proteins are secreted on exosomes [J]. Nat Cell Biol, 2012, 14(10): 1036-1045.
[15] Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways [J]. Cell, 2014, 159(3): 499-513.
[16] Hassanpour M, Rezabakhsh A, Rezaie J, er al. Exosomal cargos modulate autophagy in recipient cells via different signaling pathways [J]. Cell Biosci, 2020, 10: 92. doi: 10.1186/s13578-020-00455-7.
[17] Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA [J]. Nat Rev Mol Cell Biol, 2018, 19(3): 143-157.
[18] Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses [J]. Genes Dev, 2011, 25(18): 1915-1927.
[19] Gloss BS, Dinger ME. The specificity of long noncoding RNA expression[J]. Biochim Biophys Acta, 2016, 1859(1): 16-22.
[20] Arcaro A. Targeting PI3K/mTOR signaling in cancer [J]. Front Oncol, 2014, 4: 84. doi: 10.3389/fonc.2014.00084.
[21] Tang XD, Zhang DD, Jia L, et al. lncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-Like receptor signaling pathway [J]. Cell Physiol Biochem, 2018, 50(1): 179-195.
[22] Cui Y, Zhang F, Zhu C, et al. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway [J]. Oncotarget, 2017, 8(11): 17785-17794.
[23] Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer [J]. BMC Res Notes, 2013, 6: 518. doi: 10.1186/1756-0500-6-518.
[24] Yu H, Xu Q, Liu F, et al. Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas [J]. J Thorac Oncol, 2015, 10(4): 645-654.
[25] Wang P, Lu S, Mao H, et al. Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of long noncoding RNAs [J]. Lung Cancer, 2015, 88(2): 147-153.

相关文章 15

[1]	孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[2]	戴建建,袁冰,张颖,林琦,袁苑,韩明勇. CT引导下¹²⁵I粒子植入治疗Ⅲ期非小细胞肺癌疗效与并发症的临床观察[J]. 山东大学学报（医学版）, 2017, 55(2): 32-37.
[3]	彭岳,冯振,谢厚耐,王晖,李猛,任万刚,刘通,彭忠民. 61例肺部多发病灶患者的外科治疗[J]. 山东大学学报（医学版）, 2017, 55(11): 42-46.
[4]	王丽丽,霍彬,王磊,汪浩,侯定坤,霍小东,王金焕,臧立,曹强,柴树德,王海涛. 亚肺叶切除联合¹²⁵I粒子植入治疗早期肺癌有效性的Meta分析与系统评价[J]. 山东大学学报（医学版）, 2017, 55(10): 76-83.
[5]	高昂, 王世江, 付正, 孙新东, 于金明, 孟雪. ¹⁸F-FDG PET/CT确定局部晚期非小细胞肺癌加量放疗靶区的可行性[J]. 山东大学学报（医学版）, 2015, 53(7): 73-77.
[6]	杨璐, 刘延国, 李际盛, 王秀问. 蟾毒灵对非小细胞肺癌顺铂化疗的增敏作用及机制[J]. 山东大学学报（医学版）, 2015, 53(3): 6-11.
[7]	高鹏, 沈方臻, 肖文静, 修元德, 周玲玲. IB期非小细胞肺癌Runx2、Ezrin表达与术后转移的相关性[J]. 山东大学学报（医学版）, 2015, 53(1): 63-66.
[8]	肖芳, 蒋卫东, 王晓红, 秦爱琼, 韩敏, 陈丽. 小鼠胰岛微血管内皮细胞外泌体的提取和鉴定方法[J]. 山东大学学报（医学版）, 2015, 53(1): 6-9.
[9]	刘淑真, 于国华. 重组人血管内皮抑制素治疗晚期非小细胞肺癌的临床观察[J]. 山东大学学报（医学版）, 2014, 52(S1): 125-126.
[10]	李鹏,刘奇,韩明勇. PET-CT、血清CEA及CYFRA21-1预测靶向药物对非小细胞肺癌疗效的研究[J]. 山东大学学报(医学版), 2012, 50(1): 129-132.
[11]	杜鲁涛1，王传新1，肖晓燕2，郑妮1，张欣1，张旭华3，王丽丽1，王顺1，董召刚1. 血浆可溶性sHLA-G检测对胃癌早期诊断的意义[J]. 山东大学学报(医学版), 2011, 49(6): 125-129.
[12]	孙颖,郑晓静,李明江,赵兴波. 米非司酮对卵巢癌细胞系SKOV3增殖和CEACAM6表达的影响[J]. 山东大学学报(医学版), 2010, 48(5): 54-57.
[13]	上官红1，肖伟1，董亮1，李玉1，田辉2，郑天郢3. 血清CYFRA21-1、NSE和CEA在肺癌诊断和评估预后中的临床价值[J]. 山东大学学报(医学版), 2010, 48(12): 134-137.
[14]	许德国,王潍博. 胃癌患者腹腔灌洗液CK19 mRNA、CEA mRNA的检测及其临床意义[J]. 山东大学学报(医学版), 2008, 46(6): 600-603.
[15]	俞新爽,韩俊庆,王兴文,盛巍,王瑜. 乳腺癌患者细胞免疫水平与预后危险因素的关系及临床意义[J]. 山东大学学报(医学版), 2007, 45(9): 934-937.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed